LUCID DIAGNOSTICS INC.(LUCD)

POST1.580.06+3.84%18:37 EDT

1.52-0.05-3.18%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Lucid Diagnostics Inc expected to post a loss of 19 cents a share - Earnings Preview
  Reuters · 12:37
  Lucid Diagnostics Inc expected to post a loss of 19 cents a share - Earnings Preview
- Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (Nccn) Guidelines NOW Include Esophageal Precancer Screening
  THOMSON REUTERS · 03-20 12:31
  Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (Nccn) Guidelines NOW Include Esophageal Precancer Screening
- Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
  PR Newswire · 03-20 12:31
  Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
- Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
  PR Newswire · 03-18
  Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
- BTIG Keeps Their Buy Rating on Lucid Diagnostics (LUCD)
  TIPRANKS · 03-18
  BTIG Keeps Their Buy Rating on Lucid Diagnostics (LUCD)
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
  PR Newswire · 03-10
  Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
- BRIEF-Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
  Reuters · 03-05
  BRIEF-Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
- Lucid Diagnostics Raises $15.3 Million in Stock Offering
  TIPRANKS · 03-05
  Lucid Diagnostics Raises $15.3 Million in Stock Offering
- Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
  THOMSON REUTERS · 03-05
  Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
- Lucid Diagnostics Prices $15.3 Million Direct Offering
  MT Newswires Live · 03-04
  Lucid Diagnostics Prices $15.3 Million Direct Offering
- Lucid Diagnostics to sell 13.94M shares at $1.10 in registered direct offering
  TIPRANKS · 03-04
  Lucid Diagnostics to sell 13.94M shares at $1.10 in registered direct offering
- Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
  PR Newswire · 03-04
  Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
- Lucid Diagnostics Inc: Announces $15.3 Million Registered Direct Offering
  THOMSON REUTERS · 03-04
  Lucid Diagnostics Inc: Announces $15.3 Million Registered Direct Offering
- Lucid Diagnostics Inc - Terminates Atm Prospectus Supplement Dated Dec 6, 2022
  THOMSON REUTERS · 03-04
  Lucid Diagnostics Inc - Terminates Atm Prospectus Supplement Dated Dec 6, 2022
- Renowned Investigators Awarded $8 Million Nih Grant to Study Lucid Diagnostics' Esoguard® in at-Risk Patients Without Symptomatic Gerd
  THOMSON REUTERS · 02-27
  Renowned Investigators Awarded $8 Million Nih Grant to Study Lucid Diagnostics' Esoguard® in at-Risk Patients Without Symptomatic Gerd
- Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD
  PR Newswire · 02-27
  Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD
- Lucid Diagnostics Regains Compliance With Nasdaq Minimum Bid Price Requirement
  THOMSON REUTERS · 02-25
  Lucid Diagnostics Regains Compliance With Nasdaq Minimum Bid Price Requirement
- Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
  PR Newswire · 02-25
  Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Lucid Diagnostics Inc - Regains Compliance With Nasdaq $1 Minimum Bid Price on Feb 24
  THOMSON REUTERS · 02-25
  Lucid Diagnostics Inc - Regains Compliance With Nasdaq $1 Minimum Bid Price on Feb 24
- BRIEF-PAVmed Regains Compliance With Nasdaq Stockholders' Equity Requirement
  Reuters · 02-18
  BRIEF-PAVmed Regains Compliance With Nasdaq Stockholders' Equity Requirement
Company Profile
Company Name
LUCID DIAGNOSTICS INC.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.luciddx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
- 03-05
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 03-04
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 03-04
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 02-24
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 01-31
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 01-31
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2024-12-20
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-12-12
  Beneficial Ownership Change
  Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
  Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
- 2024-11-29
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-11-18
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-11-13
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-11-12
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-11-12
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-08-12
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-08-12
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report

1D
5D
Day
Week
Month

Loading ...

High

1.60

Open

1.56

Volume%

1.12

Low

1.51

1.57

T/O Rate

5.79%

抱歉，当前请求异常(-1)

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

LUCID DIAGNOSTICS INC.(LUCD)

Company Profile